Applied Materials Today | VOL. 19
Read

A biodegradable thermosensitive hydrogel vaccine for cancer immunotherapy

Publication Date Jun 1, 2020

Abstract

Abstract Although existing nanomaterial-based strategies for the recruitment and activation of dendritic cells (DCs) for cancer immunotherapy have achieved promising results, many issues related to safety and effectiveness remain unresolved. Simpler and safer designs are thus urgently required to eradicate tumors. In this study, we engineered an injectable and biodegradable thermosensitive hydrogel vaccine encapsulating GM-CSF, CpG-ODN (a TLR 9 agonist) and tumor cell lysates (TLs). The results confirm that this formulation of the vaccine can significantly activate and mature DCs both in vitro and in vivo due to its ability to release immunomodulators and antigens in a sustained manner. Surprisingly, on day 14, compared to controls, the hydrogel vaccine maintained a higher level of tumor necrosis factor (TNF) in the serum, which suggested it promoted a direct killing effect on tumors. When B16F10 or C26 tumors were immunized with TLs, the hydrogel vaccine observably delayed tumor growth and prolonged overall survival time in both prophylactic and therapeutic trials. In addition, an optimal formulation of this system was established to achieve the most effective inhibition of tumors. Our findings suggest that this hydrogel system may serve as an easily manufactured vaccine delivery platform for cancer immunotherapy.

Concepts

Level Of Tumor Necrosis Factor Activation Of Dendritic Cells Tumor Cell Lysates C26 Tumors Biodegradable Hydrogel Mature Dendritic Cells Hydrogel System Recruitment Of Dendritic Cells Therapeutic Trials Safer Designs

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Coronavirus Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Introduction: Test solutions (Biotrue, renu Advanced [Bausch and Lomb], ACUVUE RevitaLens [Johnson and Johnson Vision], cleadew [Ophtecs corp.] or AOS...

Read More

Good health Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  2

Patient and public involvement in health care is considered indispensable in the way we conduct daily pediatric neurology practice, and in the develop...

Read More

Quality Of Education Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Ingenta is not the publisher of the publication content on this website. The responsibility for the publication content rests with the publishers prov...

Read More

Gender Equality Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  3

Introduction: As of early March 2022, the COVID-19 pandemic has killed more 5.9 million people worldwide, and infected more than 437 million.

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.